Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
**SNX29 antisense RNA 1 (SNX29-AS1)** is most likely a presumed or inferred long non-coding RNA (lncRNA) transcribed from the antisense strand relative to the *Sorting nexin 29* (SNX29) gene. However, no authoritative gene or RNA database entries specifically identify "SNX29-AS1." The related genes and RNAs, such as SNX29 (Sorting nexin 29, a protein-coding gene[3][7]) and other lncRNAs with "-AS1" designations, are documented, but "SNX29-AS1" does not appear in major sources such as NCBI Gene, GeneCards, or The Human Protein Atlas for humans or model organisms as of the latest available data. Therefore, this target name is likely incorrect, missing, or only sparsely characterized in the literature. **Explanation and Supporting Details:** - *SNX29* is a well-described protein-coding gene encoding sorting nexin 29, involved in lipid metabolism, vesicular transport, and potentially in reproductive and neurodevelopmental traits[1][3][7]. - “AS1” designations generally indicate a non-coding RNA (lncRNA) antisense to a corresponding protein-coding gene, but “SNX29-AS1” is not documented in standardized databases or research literature as of 2025 in relation to the SNX29 locus. - There is no evidence that “SNX29-AS1” encodes a therapeutic target (receptor, enzyme, transporter, etc.) nor are there any validated drug interactions, disease roles, or associated mechanisms. - Thus, this entry is likely based on a misnomer, speculative annotation, or an uncharacterized transcript, and should be flagged as incorrect or insufficient for structured biological database inclusion.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on SNX29 antisense RNA 1 (SNX29-AS1).